HUTCHMED (China) Limited(HCM)Earnings, Financials & Key RatiosHUTCHMED (China) Limited (HCM) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2025Q2
while the balance sheet is bolstered by $1.4B in cash, the lack of consistent operational profitability and the -1.3% operating margin suggest significant execution risk remains.
HUTCHMED (China) Limited (HCM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
HUTCHMED (China) Limited (HCM) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | —vs $2.50 | $271Mvs $291M-6.7% |
| Q3 2025 | Aug 7, 2025 | $1.30vs $1.46-11.0% | $139Mvs $330M-58.0% |
| Q3 2025 | Jul 2, 2025 | $1.30 | $139M |
| Q2 2025 | Mar 19, 2025 | $0.03vs $0.09+137.9% | $162Mvs $319M-49.2% |
Recent stock market news and headlines for HUTCHMED (China) Limited (HCM)
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
AI-driven hiring and HR automation are reshaping HCM software, with three companies, namely, PAYC, PCTY and FA standing out for short-term upside.
SEATTLE--(BUSINESS WIRE)--Syndio, the Decision Intelligence for Pay company, today announced the acquisition of Embrace.ai, an agentic AI company built to deploy AI-driven automation across business workflows. The full Embrace.ai team, led by founders and enterprise software veterans Derek Butts and Seth Halpern, will join Syndio's product and go-to-market organization. The acquisition bolsters the Syndio team with deep experience across enterprise human capital management (HCM), large-scale so.
LAS VEGAS, June 16, 2026 (GLOBE NEWSWIRE) -- Connect For Partners -- isolved ® today unveiled the first autonomous AI agents built to own HR, payroll and benefits outcomes, and launched general availability of the isolved Connector for Claude. The announcement arrives as AI agents proliferate inside the American workforce without systems of record, governance, or accountability — a workforce problem disguised as a software problem.
Key metrics vs top competitors for HUTCHMED (China) Limited (HCM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.65 | $2.03B | 4.48 | -12.73% | 83.3% | 45.29% | — | |
| $19.08 | $2.11B | -11.93 | 15.33% | -39.29% | -24.32% | — | |
| $28.04 | $5.19B | -17.53 | 64.04% | -21.97% | -24.91% | — | |
| $0.29 | $184M | -0.64 | 96.69% | -39.68% | -60.72% | — | |
| $254.76 | $450.11B | 107.49 | 8.57% | 5.79% | 67.46% | — | |
| $126.78 | $313.12B | 17.41 | 1.18% | 13.62% | 17.91% | — |
HUTCHMED (China) Limited (HCM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when HCM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HUTCHMED (China) Limited (HCM) stock FAQ — growth, dividends, profitability & financials explained
HUTCHMED (China) Limited (HCM) reported $602.2M in revenue for fiscal year 2025. This represents a 1491% increase from $37.9M in 2005.
HUTCHMED (China) Limited (HCM) saw revenue decline by 12.7% over the past year.
Yes, HUTCHMED (China) Limited (HCM) is profitable, generating $466.9M in net income for fiscal year 2025 (83.3% net margin).
HUTCHMED (China) Limited (HCM) has a return on equity (ROE) of 45.3%. This is excellent, indicating efficient use of shareholder capital.
HUTCHMED (China) Limited (HCM) had negative free cash flow of $49.7M in fiscal year 2025, likely due to heavy capital investments.
